- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06060145
Effect of Indoor Plants on Cardiopulmonary System
October 2, 2023 updated by: Lina Zhang
Effect of Indoor Plants on Cardiopulmonary System: a Randomized, Crossover, Controlled Trial
This is a randomized controlled human exposure crossover study, aims to explore the health benefits of indoor plants on cardiopulmonary system on adults.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
The researchers will conduct a randomized cross-controlled trial involving 48 healthy adults in Hangzhou, China.
These participants will be randomly assigned into two groups, each comprising 24 individuals.
Each participant will undergo two separate exposures in an office setting: one exposure without any plants present, and another exposure with 34 to 38 potted plants.
A washout period of at least 4 weeks will be implemented between the two exposures.
Questionnaires, physical examinations and the collection of biological samples will be conducted prior to exposure and after exposure.
In addition, the monitoring of negative air ion, air pollutants and noise exposure, as well as collection of environmental microbial samples, will be conducted on weekdays.
Researchers will gather samples of blood, urine, nasal secretion, and exhaled breath condensate from participants.
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lina Zhang, Ph.D
- Phone Number: +8618540103321
- Email: zhanglina@zcmu.edu.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Living in Hangzhou during the study period;
- Non-smoking, no history of alcohol or drug abuse;
- Staying indoors in daytime we required.
Exclusion Criteria:
- Current or ever smokers;
- Subjects with allergic disease, such as allergic rhinitis, allergic asthma, and atopy;
- Subjects with cardiovascular disease, such as congenital heart disease, pulmonary heart disease, and hypertension;
- Subjects with respiratory disease, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease;
- Subjects with chronic disease, such as diabetes, chronic hepatitis, and kidney disease;
- Subjects with a history of major surgery;
- Medication use or dietary supplements intake in recent two months;
- Unable to cooperate with follow-up.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Plants placed in an office environment
Participants in this group will receive an intervention of plants placed in an office environment.
|
The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
|
Active Comparator: Devoid of any plant presence in an office environment
Participants in this group will be exposed to an office environment devoid of any plant presence.
|
Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Forced Vital Capacity(FVC)
Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
We plan to measure forced vital capacity (FVC) of lung function.
|
Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure(BP)
Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
We plan to measure systolic blood pressure (SBP) and diastolic blood pressure (DBP).
|
Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
Heart Rate Variability(HRV)
Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
We plan to measure Heart Rate Variability (HRV).
|
Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-reactive protein(CRP)
Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
We plan to measure serum concentrations of C-reactive protein(CRP)
|
Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
Interleukin-6(IL-6)
Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
We plan to measure the serum concentrations of Interleukin-6
|
Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
Tumor necrosis factor-α(TNF-α)
Time Frame: Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
We plan to measure the serum concentrations of Tumor necrosis factor-α
|
Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lina Zhang, Ph.D, School of Public Health, Zhejiang Chinese Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 16, 2023
Primary Completion (Estimated)
January 13, 2024
Study Completion (Estimated)
January 13, 2024
Study Registration Dates
First Submitted
September 23, 2023
First Submitted That Met QC Criteria
September 23, 2023
First Posted (Actual)
September 29, 2023
Study Record Updates
Last Update Posted (Actual)
October 5, 2023
Last Update Submitted That Met QC Criteria
October 2, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 20230922-4
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiopulmonary
-
Baxter Healthcare CorporationCompletedCardiopulmonary Bypass | Sternotomy | Cardiac Surgery Requiring Cardiopulmonary Bypass and Median SternotomyUnited States
-
Universidade do PortoCentro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS); Rede... and other collaboratorsRecruitingCardiopulmonary ResuscitationPortugal
-
Tampere University HospitalNational Istitute For Health and Welfare, FinlandRecruiting
-
University Hospital, GhentCompletedCardiopulmonary Bypass
-
Aristotle University Of ThessalonikiCompletedHeparin and Protamine Titration in Cardiac Surgery Under Minimal Invasive Extracorporeal CirculationCardiopulmonary BypassGreece
-
National Taiwan University HospitalCompletedCardiopulmonary ResuscitationTaiwan
-
Medical University of ViennaSt. John's Ambulance, Vienna Austria; Universitäres Simulationszentrum Wien...Completed
-
University Medical Centre LjubljanaSlovenian Research AgencyCompleted
-
The Royal Wolverhampton Hospitals NHS TrustCompletedCardiopulmonary ResuscitationUnited Kingdom
-
Peking Union Medical College HospitalUnknownCardiopulmonary ResuscitationChina
Clinical Trials on Plants placed in an office environment
-
Colorado State UniversityHearts and Horses Therapeutic Riding CenterCompletedPiloting an Enhanced Protocol of Occupational Therapy in an Equine Environment for Youth With AutismAutism Spectrum DisorderUnited States
-
Pennington Biomedical Research CenterCompletedEnergy ExpenditureUnited States
-
University of California, San FranciscoHealth Resources and Services Administration (HRSA); The New York Academy of... and other collaboratorsCompletedHIV | Opioid Dependence | BuprenorphineUnited States